Bluestar Genomics Closes $70M Series C Funding, Expands Scientific Advisory Board

SAN DIEGO, May 17 (Bernama-BUSINESS WIRE) — Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, today announced the company had raised $70 million in new equity funding. Led with the increased funding by the current investor, Mattias Westman, founding partner of Prosperity Capital Management, the oversubscribed Series C round includes several existing investors and multiple new investors: Pathology Asia Holdings Pte Ltd (Pathology Asia), the largest independent medical diagnostics group in Southeast Asia, as well as a venture fund based in San Francisco, CA, and a large, diversified asset manager on the west coast, among others. VAHOCA Pte Ltd acted as a financial advisor to Bluestar Genomics.

Separately, the company announces the expansion of its Scientific Advisory Board, with the appointment of Drs. Felix Feng, professor of radiation oncology, urology, and medicine, University of California San Francisco, and Craig Venter, Ph.D., chairman and CEO of the J. Craig Venter Institute. With the new appointment, Feng and Venter are joining Alan Ashworth, Ph.D., FRS, president, Helen Diller Comprehensive Cancer Center, University of California, San Francisco.

http://mrem.bernama.com/viewsm.php?idm=40048

administrator

Related Articles